Hoth Therapeutics (HOTH) announced its intention to submit an Expanded Access application for HT-001, its novel therapeutic candidate for the treatment of dermatological conditions associated with cancer therapy. HT-001 is being developed to alleviate the adverse dermatological effects experienced by cancer patients undergoing epidermal growth factor receptor inhibitor treatments. With positive progress in ongoing clinical studies, Hoth Therapeutics aims to provide patients access to HT-001 outside of traditional clinical trials through the Expanded Access Program, commonly known as “compassionate use.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HOTH:
- Hoth Therapeutics reports ‘promising’ results for HT-001 therapeutic candidate
- Hoth Therapeutics’ GDNF shows efficacy in obesity prevention and reversal
- Hoth Therapeutics announces collaboration with OnTargetx R&D
- Hoth Therapeutics regains compliance with Nasdaq listing rules
- Hoth Therapeutics expands IP portfolio with patent application acquisitions
Questions or Comments about the article? Write to editor@tipranks.com